Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease

ObjectiveCompared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ open diabetes research & care 2020-01, Vol.8 (1), p.e000991, Article 000991
Hauptverfasser:	Mayeda, Laura, Katz, Ronit, Ahmad, Iram, Bansal, Nisha, Batacchi, Zona, Hirsch, Irl B, Robinson, Nicole, Trence, Dace L, Zelnick, Leila, de Boer, Ian H
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged Amputation Biomarkers - analysis Blood Glucose - analysis Blood Glucose Self-Monitoring Case-Control Studies Diabetes Diabetes Mellitus, Type 2 - complications Diabetic retinopathy Endocrinology & Metabolism Epidemiology Family medical history Female Follow-Up Studies Foot diseases Glomerular Filtration Rate Glucose monitoring Glycated Hemoglobin A - analysis Hemoglobin Humans Hyperglycemia Kidney diseases Life Sciences & Biomedicine Male Middle Aged Pathophysiology/Complications Peripheral Nervous System Diseases - diagnosis Peripheral Nervous System Diseases - etiology Peripheral Nervous System Diseases - metabolism Peripheral neuropathy Prognosis Prospective Studies Questionnaires Renal Insufficiency, Chronic - complications Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ObjectiveCompared with hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) may better capture risk of diabetes complications in patients with chronic kidney disease (CKD), including diabetic peripheral neuropathy (DPN). We hypothesized that glucose time in range (TIR), measured by CGM, is associated with DPN symptoms among participants with type 2 diabetes mellitus (type 2 DM) and moderate-to-severe CKD.Research design and methodsWe enrolled 105 people with type 2 DM treated with insulin or sulfonylurea, 81 participants with CKD (estimated glomerular filtration rate (eGFR)
ISSN:	2052-4897 2052-4897
DOI:	10.1136/bmjdrc-2019-000991